Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serelaxin To Lower Portal Pressure in Patients with Cirrhosis and Portal Hypertension (STOPP)

Next Previous
X
Search
Trial Profile

Serelaxin To Lower Portal Pressure in Patients with Cirrhosis and Portal Hypertension (STOPP)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Liver cirrhosis; Portal hypertension
  • Focus Proof of concept; Therapeutic Use
  • Acronyms STOPP

    • Most Recent Events

    • 30 Jul 2020 Status changed from recruiting to discontinued.
    • 08 Feb 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
    • 08 Feb 2018 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top